A Glimpse Into The Expert Outlook On Azenta Through 4 Analysts

During the last three months, 4 analysts shared their evaluations of Azenta AZTA, revealing diverse outlooks from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $69.5, a high estimate of $79.00, and a low estimate of $55.00. Marking an increase of 7.75%, the current average surpasses the previous average price target of $64.50.

Investigating Analyst Ratings: An Elaborate Study

The perception of Azenta by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Azenta. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Azenta compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Azenta's stock. This examination reveals shifts in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Azenta's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Azenta analyst ratings.

About Azenta

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Unraveling the Financial Story of Azenta

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Positive Revenue Trend: Examining Azenta's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.29% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Azenta's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.96% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Azenta's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.13%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Azenta's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.11%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Azenta's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.

The Basics of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.